HER2-negative status in breast cancer patients may be an indicator that up-front aromatase inhibitor (AI) therapy, or switching from tamoxifen to AI, will reduce the risk for distant relapse, according to a recent meta-analysis.
Investigators affiliated with the Trans-AIOG (Translational Aromatase Inhibitor Overview Group) analyzed patient data from three Phase III trials—ATAC (Arimidex, Tamoxifen, Alone or in Combination Trial), BIG (Breast International Group 1-98) and TEAM (Tamoxifen